Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
NCT03498612Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Jul 2018
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in follicular lymphoma (FL), marginal zone lymphoma (MZL), B-cell non-Hodgkin lymphoma, sponsored by University of Washington. Started Jul 2018; status: terminated.
02
Drugs
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03498612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498612.